Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC

Carcinoma of Urinary Bladder, Superficial Clinical Trial

— OPTIMA  

Official title:

Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01803295
• Other study ID #: TAS-4M-CS-0002-0
• Status: Completed
• Phase: N/A
• First received: February 21, 2013
• Last updated: June 15, 2017
• Start date: June 2013
• Est. completion date: June 2017

Study information

• Verified date: June 2017
• Source: UroGen Pharma Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the proposed study the investigators aim to evaluate the effect of the standard of care dose (40mg) of MMC mixed with TC-3 gel (with sustained release mechanism on the drug) on low risk recurrent NMIBC lesions and to compare our findings to instillation with the standard mode of instillation- 40mg MMC in water in order to examine our hypothesis that MMC mixed with TC-3 gel will have at least non-inferior and even superior results over the standard instillation mode

The investigators believe that this study is of importance of several aspects:

1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode.

2. If proved effective this mode of treatment might save the need of TURBT performance and serve as a new mode of tumor ablation.

3. Even if proved partially effective this mode of treatment will diminish tumors size or number thus enable a more limited TURBT procedure.

4. This mode of treatment will enable immediate medical attendance to the patient's tumor recurrence without the waiting period (resulting from queues in the medical centers) for TURBT, which might improve the patient's prognostic outcome.

5. If this experimental treatment will prove to have a better ablative effect, this could be translated to a better prophylactic effect of tumor recurrence.

Description:

Non-muscle-Invasive Bladder cancer is mainly treated by tumor resection (Trans Urethral Resection - TUR), followed by series of intravesical instillations of prophylactic chemotherapeutic drugs as Mitomycin C (MMC) or BCG. This treatment approach is limited due to rapid dilution the chemotheraputic drug by the incoming urine and clearance by urination.

TheraCoat core technology is based on a reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.

Prior to instillation, the TC-3 hydrogel, in a liquid state, is mixed with MMC.TC-3 mixed with MMC is instilled to the bladder by a catheter. Following gel insertion to the bladder, the gel solidifies and forms a drug reservoir inside the bladder. Upon contact with urine the gel dissolves and is cleared out from the bladder.

Intravesical MMC instillation using TheraCoat gel is expected to increase treatment efficiency due to prolongation of treatment duration and consequently improving bladder exposure to MMC.

Treatment Protocol - Immediately following baseline cystoscopy and tumor diagnosis and patient undergoes 6 weekly instillations followed by 2-4 weeks healing period.

1st Follow-Up Visit (Pre-Scheduled TURBT Visit): The patient will undergo a second Cystoscopy to compare to the Baseline status and after that a follow-up period: 3,6,9,12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: June 2017
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Patient is 21 years of age or older.

2. Patient has signed Informed Consent Form and is willing and able to abide by the protocol.

3. Naïve or recurrent low grade (LG) NMIBC tumor

4. Recurrent patients - Single or multiple tumors

5. Naive patients - 2 tumors or above

6. No prior history of HG and/or T1 in the past 5 years.

7. No prior history of Tis

8. At least one Tumor = 1 mm as evaluated visually by the investigator.

9. Largest tumor diameter = 30 mm as evaluated visually by the investigator

10. Cystoscopic appearance of papillary Low grade tumor

11. No active urinary tract infection as confirmed by urine culture

12. If the patient is a female of childbearing potential , she is using two acceptable & effective methods of contraception , until 6 months post treatment

13. If the patient is a male he should use a condom during intercourse, for at least 48 hours post each instillation

14. If the patient is a male that has a partner that is a female of childbearing potential, he should be advised to use two acceptable & effective methods of contraception until 6 months post treatment.

Exclusion Criteria:

1. Carcinoma In Situ (CIS).

2. "High Grade" urine cytology which is conclusive for HG.

3. "High Grade" tumor results in cold cup biopsy.

4. Tumor located in prostatic urethra.

5. Previous systemic chemotherapy in the last 2 years or pelvic radiotherapy.

6. Pregnant or breastfeeding patient.

7. Previous treatment with BCG within the last 12 months.

8. The patient did not have at least 3 months cystoscopically confirmed tumor-free interval between the last TURBT to current tumor recurrence.

9. Treatment with full course of intravesical chemotherapy within the 3 last months.

10. The patient has/had any bladder tumor with histology other than TCC.

11. Known contraindication or hypersensitivity to MMC or gel.

12. The patient has a known history of upper urinary tract urothelial carcinoma, or Renal Cell carcinoma or other renal cancer.

13. The patient has a known urinary retention which, according to the investigator's opinion, might lead to avoid patient receiving the treatment.

14. The patient has a bleeding disorder or a screening platelet count <50X109/L.

15. The patient has screening hemoglobin <10 mg/dL.

16. The patient has a condition or a concurrent severe and/or uncontrolled medical or psychiatric disease (e.g. uncontrolled diabetes, compensated congestive heart failure (NYHA III and over), myocardial infarction within 6 months of study, unstable or uncontrolled hypertension or an active uncontrolled infection), which could compromise participation, compliance with scheduled visits and/or completion.

17. The patient participated in an investigational interventional study within the past 90 days.

18. The patient has documented sever vesico-ureteral reflux or an indwelling ureteral stent.

19. The patient has the tumor in the bladder diverticulum.

20. The patient participated in a prior TheraCoat's trial with MMC and TC-3

Related Conditions & MeSH terms

• Carcinoma of Urinary Bladder, Superficial
• Urinary Bladder Neoplasms

Intervention

Device:
• 40 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.

Other:
• Standard of care MMC mixed with water
Standard of care 40mg MMC mixed with water

Device:
• 80 mg MMC gel
A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder

Locations

Country	Name	City	State
Israel	Carmel Medical Center of Haifa, Department of Urology	Haifa
Israel	Rambam Health Care Campus	Haifa
Israel	Wolfson Medical Center of Holon, Department of Urology	Holon
Israel	Meir medical center	Kfar Saba
Israel	Galil Maaravi Medical Center of Nahariya, Department of Urology	Nahariya
Israel	Rabin Medical Center of Petah Tikva, Department of Urology	Petach Tikvah
Israel	Ziv Medical Center	Zefat
Italy	Vita Salute University, San Raffaele Hospital of Milan, Department of Urology	Milan
Italy	S. Andrea Hospital of Rome, Department of Urology	Rome
Italy	Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona	Salerno
Spain	Fundacio Puigvert	Barcelona
Spain	Hospital Universitario Infanta Sofìa of Madrid, Department of Urology	Madrid
Switzerland	Hôpital HUG of Geneva, Department of Urology	Geneva

Sponsors (1)

Lead Sponsor	Collaborator
UroGen Pharma Ltd.

Countries where clinical trial is conducted

Israel,  Italy,  Spain,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Comparison of the cystoscopic and pathological effect between the 2 groups.	• Comparison of the cystoscopic and pathological effect of pre-TURBT instillations with MMC mixed with TC-3 Hydrogel on bladder lesion(s) to that of pre-TURBT MMC in water instillation groups	2 years
Other	• Comparison of one year tumor recurrence rate between both treatment groups		2 years
Other	• Demonstration that blood levels of MMC following Pre-TURBT TC-3 gel-MMC instillation are below the toxic level (400ng/ml) known in the art for IV MMC administration		1 year
Primary	ablative effect of pre-TURBT intravesical instillations of the treatments on The bladder lesion(s) of NMIBC patients	Cystoscopic and pathological effect (evaluated during TUR-BT visit) of pre-TURBT intravesical instillations with 40 mg of MMC mixed with 60cc TC-3 Hydrogel on bladder lesion(s) of NMIBC patients. At To, which is the time of identification of a recurrent tumor by cystoscopy, the number, size and location of the lesions will be documented and photographed. Each tumor size will be evaluated by photographing a ureter catheter adjacent to the tumor. Since the ureter catheter diameter is a pre-known variable, the tumor diameter can be calculated using specific software developed for study purposes. Photography of the tumor with a pre-known diameter ureter catheter will be performed during the same cystoscopy as described above and will be evaluated by a central clinic for uniformity of measurements, and the results of these measurements will serve for the post study evaluation of the change in tumor diameter	2 years
Primary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability rate.	Demonstration of Pre-TURBT TC-3 gel-MMC instillation safety and adverse event rate.Adverse events will be defined as any adverse change in health or side effect that occurs in the clinical trial participant while the patient is receiving the treatment or until the completion of the post-treatment follow-up cystoscopy.	2 years